AltSonflex1-2-3 Medium Dose

Preclinical

GSK

AltSonflex1-2-3 Medium Dose is one of 3 therapeutic programs targeting Diarrhoea. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

DiarrhoeaCompleted

DiarrhoeaPreclinical

Completed

Competition

Competitive Landscape

5 competitors in Diarrhoea

#DrugCompanyPhaseTrials

MR-Vac

GSK

Preclinical

1 2

Menveo

GSK

Preclinical

1 3

AltSonflex1-2-3 Medium Dose

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diarrhoea1 trial

A Staged Phase I/II Observer-blind, Randomised, Controlled, Multi-country Study to Evaluate the Safety, Reactogenicity, and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against S. Sonnei and S. Flexneri, Serotypes 1b, 2a, and 3a, in Adults in Europe (Stage 1) Followed by Age De-escalation From Adults to Children and Infants, and Dose-finding in Infants in Africa (Stage 2)

Completed· GSK logo

GSK·Preclinical·NCT05073003·551 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AltSonflex1-2-3 Medium Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for AltSonflex1-2-3 Medium Dose. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: GSK

AltSonflex1-2-3 Medium Dose

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Diarrhoea1 trial

References

Drug Info

Quick Facts

Related News